These findings are supported by studies in which recombinant adiponectin given to obese mice not only ameliorated hepatomegaly, hepatic steatosis and inflammation but also normalized levels of alanine aminotransferase (ALT) [253] which is a sensitive indicator of liver injury and often used as a surrogate marker for NAFLD [254]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.